title: Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment.
abstract: OBJECTIVE
  To evaluate the results of controlled ovarian stimulation before chemotherapy for oocyte vitrification to preserve fertility in women diagnosed with cancer and compare them with a historical control group.
  
  
  METHODS
  A retrospective, multicenter, observational study performed between March 2007 and January 2011.
  
  
  METHODS
  University-affiliated infertility clinics.
  
  
  METHODS
  Of 272 patients affected by cancer in our Fertility Preservation Program, 223 women underwent a stimulated cycle for oocyte vitrification according to our protocols before cancer treatment. Their results were compared with a historical control group of 98 patients diagnosed with male factor infertility who were stimulated for a conventional IVF cycle.
  
  
  METHODS
  Controlled ovarian stimulation and oocyte retrieval.
  
  
  METHODS
  Days of stimulation, total dose of gonadotropins, estrogen levels, and number of oocytes retrieved and vitrified.
  
  
  RESULTS
  No differences were found in days of stimulation, but significant differences in E(2) levels and the number of retrieved oocytes were measured, especially in the hormone-dependent cancer group.
  
  
  CONCLUSIONS
  Patients with hormone-dependent cancer had a weaker response to controlled ovarian stimulation compared with patients with non-hormone-dependent cancer. Whether the oncological disease already affects the ovaries before chemo-/radiotherapy remains to be elucidated.
authors.affiliation: IVI Las Palmas, Las Palmas, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Domingo
authors.forename: Vicente
authors.initials: V
authors.lastname: Guillén
authors.forename: Yanira
authors.initials: Y
authors.lastname: Ayllón
authors.forename: María
authors.initials: M
authors.lastname: Martínez
authors.forename: Elkin
authors.initials: E
authors.lastname: Muñoz
authors.forename: Antonio
authors.initials: A
authors.lastname: Pellicer
authors.forename: Juan A
authors.initials: JA
authors.lastname: Garcia-Velasco
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015925:Cryopreservation; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D059247:Fertility Preservation / Q000379:methods*; D006801:Humans; D007247:Infertility, Female / Q000139:chemically induced / Q000503:physiopathology / Q000628:therapy*; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000503:physiopathology; D054315:Oocyte Retrieval; D009865:Oocytes / Q000187:drug effects*; D010060:Ovulation / Q000187:drug effects / Q000528:radiation effects; D010062:Ovulation Induction; D012189:Retrospective Studies; D013030:Spain; D013997:Time Factors; D058989:Vitrification; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D005300:Fertility Agents, Female